News Briefs

VC-backed biopharma company Mineralys Therapeutics raises $192m for IPO

The stock began trading February 10, 2023 on the NASDAQ under the ticker symbol "MLYS."

-
  • BofA Securities, Evercore ISI, Stifel, Guggenheim Securities, Credit Suisse and Wells Fargo Securities are serving as underwriters
  • Mineralys is developing medicines to target diseases driven by abnormally elevated aldosterone
  • Mineralys’ pre-IPO backers include RA Capital Management, Andera Partners, RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysios Capital, HealthCor Management and Boulder Ventures

Radnor, Pennsylvania-based Mineralys Therapeutics, a clinical-stage biopharmaceutical company, has raised $192 million for its IPO after pricing its 12 million shares at $16 per share.

The stock began trading February 10, 2023 on the NASDAQ under the ticker symbol “MLYS.”

BofA Securities, Evercore ISI, Stifel, Guggenheim Securities, Credit Suisse and Wells Fargo Securities are serving as underwriters.

Mineralys is developing medicines to target diseases driven by abnormally elevated aldosterone.

Mineralys’ pre-IPO backers include RA Capital Management, Andera Partners, RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysios Capital, HealthCor Management and Boulder Ventures.